Proud father of twin girls, husband, vascular and endovascular surgeon at Vancouver General Hospital, program director ubc vascular and surgical foundations
- Tweets535
- Following178
- Followers294
- Likes125
ALT This image consists of two Kaplan-Meier survival curves comparing selpercatinib (blue line) and placebo (gray line) in event-free survival for both the primary analysis population and overall population. Tables accompany each chart, detailing the number of patients at risk and related statistics.
ALT This image is a forest plot showing hazard ratios for disease recurrence, progression, or death across different subgroups. Subgroups include overall, sex, age, geographic region, smoking status, ECOG performance status, disease stage, and previous chemotherapy. Each subgroup lists the total number of patients, number of patients with events for selpercatinib and placebo, and a corresponding hazard ratio with a confidence interval.
ALT The image is from a Research Summary published in the New England Journal of Medicine about catheter-directed fibrinolysis for pulmonary embolism. It includes data on 544 adult patients with an average age of 58. The study compares an intervention group receiving ultrasound-facilitated, catheter-directed fibrinolysis with alteplase and anticoagulation (273 patients) and a control group receiving anticoagulation alone (271 patients). Illustrations show medical devices and a diagram of the lungs.
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
ALT Original Article | APR 16, 2026 Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE) Figure 1A. Cumulative Incidence of Ischemic Stroke.
ALT The New England Journal of Medicine Perioperative Enfortumab Vedotin–Pembrolizumab in Bladder Cancer A Research Summary based on Vulsteke C et al. | 10.1056/NEJMoa2511674 | Published on February 18, 2026 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
ALT American College of Cardiology Annual Meeting Original Article | MAR 30, 2026 | NEJM.org Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease (SirPAD) Figure 1. Cumulative Incidence of a Primary-Outcome Event.
ALT Figure 3. Algorithm for management of acute ischemic stroke (AIS) eligibility for endovascular thrombectomy (EVT) for large core infarct.
ALT The Society of Vascular and Interventional Neurology 2025 Annual Meeting Original Article | NOV 21, 2025 | NEJM.org Medical Management and Revascularization for Asymptomatic Carotid Stenosis Figure 2A. Primary-Outcome Analysis. The NEJM signature sits at the bottom.
